• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

人类结直肠肿瘤中的纤溶酶原激活剂

Plasminogen activators in human colorectal neoplasia.

作者信息

Gelister J S, Mahmoud M, Lewin M R, Gaffney P J, Boulos P B

出版信息

Br Med J (Clin Res Ed). 1986 Sep 20;293(6549):728-31. doi: 10.1136/bmj.293.6549.728.

DOI:10.1136/bmj.293.6549.728
PMID:3094628
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1341448/
Abstract

A crucial step in the transition from adenomatous polyp to invasive colorectal cancer is the degradation of the epithelial basement membrane. Plasminogen activators may play a part in regulating the extracellular protease environment necessary for this to occur. Both functional and antigenic activity of the two principal activators of plasminogen, tissue plasminogen activator and urokinase, were measured in 30 colorectal cancers, matched samples of mucosa, and eight adenomatous polyps. Both polyps (p less than 0.01) and carcinomas (p less than 0.001) had raised urokinase activities compared with normal mucosa, the activity being highest in the carcinomas. Activity of tissue plasminogen activator, however, was diminished in both polyps (p less than 0.01) and carcinomas (p less than 0.001) compared with normal mucosa, the values being lowest in carcinomas. Plasmin generation by urokinase--in contrast with tissue plasminogen activator--is fibrin independent and thus less subject to physiological control.

摘要

从腺瘤性息肉转变为浸润性结直肠癌的关键步骤是上皮基底膜的降解。纤溶酶原激活剂可能参与调节发生这种情况所需的细胞外蛋白酶环境。在30例结直肠癌、匹配的黏膜样本和8例腺瘤性息肉中,对纤溶酶原的两种主要激活剂,即组织纤溶酶原激活剂和尿激酶的功能及抗原活性进行了测定。与正常黏膜相比,息肉(p<0.01)和癌(p<0.001)的尿激酶活性均升高,癌中的活性最高。然而,与正常黏膜相比,息肉(p<0.01)和癌(p<0.001)中的组织纤溶酶原激活剂活性均降低,癌中的值最低。与组织纤溶酶原激活剂不同,尿激酶产生纤溶酶不依赖于纤维蛋白,因此较少受生理控制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a52a/1341448/bf175ea21390/bmjcred00252-0024-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a52a/1341448/bf175ea21390/bmjcred00252-0024-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a52a/1341448/bf175ea21390/bmjcred00252-0024-a.jpg

相似文献

1
Plasminogen activators in human colorectal neoplasia.人类结直肠肿瘤中的纤溶酶原激活剂
Br Med J (Clin Res Ed). 1986 Sep 20;293(6549):728-31. doi: 10.1136/bmj.293.6549.728.
2
Plasminogen activators in experimental colorectal neoplasia: a role in the adenoma-carcinoma sequence?实验性结直肠肿瘤中的纤溶酶原激活剂:在腺瘤-癌序列中起作用?
Gut. 1987 Jul;28(7):816-21. doi: 10.1136/gut.28.7.816.
3
Plasminogen activators and tumor development in the human colon: activity levels in normal mucosa, adenomatous polyps, and adenocarcinomas.纤溶酶原激活剂与人类结肠癌的发展:正常黏膜、腺瘤性息肉及腺癌中的活性水平
Cancer Res. 1987 Sep 1;47(17):4654-7.
4
Imbalance of plasminogen activators and their inhibitors in human colorectal neoplasia. Implications of urokinase in colorectal carcinogenesis.人结直肠肿瘤中纤溶酶原激活剂及其抑制剂的失衡。尿激酶在结直肠癌发生中的意义。
Gastroenterology. 1991 Dec;101(6):1522-8. doi: 10.1016/0016-5085(91)90387-z.
5
Plasminogen activators and inhibitor type 1 in neoplastic colonic tissue from patients with familial adenomatous polyposis.家族性腺瘤性息肉病患者肿瘤性结肠组织中的纤溶酶原激活剂和1型抑制剂
Br J Cancer. 1995 Feb;71(2):393-6. doi: 10.1038/bjc.1995.80.
6
Plasminogen activators in normal tissue and carcinomas of the human oesophagus and stomach.人食管和胃癌组织及正常组织中的纤溶酶原激活剂
Gut. 1993 Jan;34(1):80-5. doi: 10.1136/gut.34.1.80.
7
Role of urokinase in colorectal neoplasia.尿激酶在结直肠肿瘤形成中的作用。
Br J Surg. 1987 Jun;74(6):460-3. doi: 10.1002/bjs.1800740607.
8
Secretion of plasminogen activators by human colorectal and gastric tumor explants.人结肠和胃肿瘤外植体中纤溶酶原激活剂的分泌
Clin Exp Metastasis. 1988 Nov-Dec;6(6):431-50. doi: 10.1007/BF01784375.
9
Urokinase-type plasminogen activator in colorectal carcinomas and adenomatous polyps: quantitative expression of active and proenzyme.尿激酶型纤溶酶原激活剂在结直肠癌和腺瘤性息肉中的表达:活性酶和酶原的定量分析
Int J Cancer. 1988 Oct 15;42(4):483-8. doi: 10.1002/ijc.2910420402.
10
Plasminogen activator content of human tumor and adjacent normal tissue measured with fibrin and non-fibrin assays.采用纤维蛋白和非纤维蛋白检测法测定人肿瘤组织及相邻正常组织中的纤溶酶原激活物含量。
Cancer Res. 1986 Apr;46(4 Pt 1):1788-94.

引用本文的文献

1
Proteolysis in colorectal cancer.结直肠癌中的蛋白水解作用。
Mol Pathol. 1999 Jun;52(3):140-5. doi: 10.1136/mp.52.3.140.
2
Alterations in plasminogen activation correlate with epithelial cell dysplasia grading in colorectal adenomas.纤溶酶原激活的改变与结直肠腺瘤中上皮细胞发育异常分级相关。
Br J Cancer. 1998;77(2):297-304. doi: 10.1038/bjc.1998.46.
3
In situ stromal expression of the urokinase/plasmin system correlates with epithelial dysplasia in colorectal adenomas.尿激酶/纤溶酶系统的原位基质表达与大肠腺瘤中的上皮发育异常相关。

本文引用的文献

1
Fibrinolytic activity of human tumors as measured by the fibrin-plate method.用人纤维蛋白平板法测定的人类肿瘤的纤溶活性。
Cancer. 1955 Nov-Dec;8(6):1146-54. doi: 10.1002/1097-0142(1955)8:6<1146::aid-cncr2820080610>3.0.co;2-w.
2
Plasminogen activator content of human colon tumors and normal mucosae: separation of enzymes and partial purification.人结肠肿瘤和正常黏膜的纤溶酶原激活物含量:酶的分离与部分纯化
J Natl Cancer Inst. 1980 Aug;65(2):345-51.
3
Procoagulant and fibrinolytic activities of gastric and colorectal cancer.胃癌和结直肠癌的促凝及纤溶活性
Am J Pathol. 1997 Jan;150(1):283-95.
4
Cathepsin B and other proteases in human colorectal carcinoma.人结直肠癌中的组织蛋白酶B及其他蛋白酶
Am J Pathol. 1994 Aug;145(2):253-62.
5
Plasminogen activators in experimental colorectal neoplasia: a role in the adenoma-carcinoma sequence?实验性结直肠肿瘤中的纤溶酶原激活剂:在腺瘤-癌序列中起作用?
Gut. 1987 Jul;28(7):816-21. doi: 10.1136/gut.28.7.816.
6
Plasminogen activators in endoscopic biopsies as indicators of gastrointestinal cancer: comparison with resection specimens.内镜活检中纤溶酶原激活剂作为胃肠道癌指标的研究:与切除标本的比较
Br J Cancer. 1989 Sep;60(3):397-400. doi: 10.1038/bjc.1989.293.
7
Disturbed fibrinolysis in patients with inflammatory bowel disease. A study in blood plasma, colon mucosa, and faeces.炎症性肠病患者的纤维蛋白溶解功能紊乱。一项关于血浆、结肠黏膜和粪便的研究。
Gut. 1989 Feb;30(2):188-94. doi: 10.1136/gut.30.2.188.
Int J Cancer. 1982 Sep 15;30(3):329-33. doi: 10.1002/ijc.2910300312.
4
Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane.纤溶酶原激活剂(尿激酶)、纤溶酶和凝血酶对基底膜糖蛋白和胶原成分的影响。
Cancer Res. 1981 Nov;41(11 Pt 1):4629-36.
5
Plasma levels of a specific inhibitor of tissue-type plasminogen activator (and urokinase) in normal and pathological conditions.正常和病理状态下组织型纤溶酶原激活物(及尿激酶)特异性抑制剂的血浆水平。
Thromb Res. 1984 Mar 1;33(5):523-30. doi: 10.1016/0049-3848(84)90018-5.
6
A model for human colon carcinoma evolution based on the differential response of cultured preneoplastic, premalignant, and malignant cells to 12-O-tetradecanoylphorbol-13-acetate.一种基于培养的癌前、恶变前和恶性细胞对12-O-十四烷酰佛波醇-13-乙酸酯的不同反应的人类结肠癌演变模型。
Cancer Res. 1984 Apr;44(4):1568-78.
7
Quantitation of tissue-type plasminogen activator in human endothelial cell cultures by use of an enzyme immunoassay.利用酶免疫测定法对人内皮细胞培养物中的组织型纤溶酶原激活剂进行定量分析。
Thromb Res. 1984 Jan 15;33(2):145-53. doi: 10.1016/0049-3848(84)90175-0.
8
Plasminogen activators of the pituitary gland: enzyme characterization and hormonal modulation.垂体中的纤溶酶原激活剂:酶的特性及激素调节
J Cell Biol. 1983 Oct;97(4):1029-37. doi: 10.1083/jcb.97.4.1029.
9
Rat mammary carcinoma cells secrete active collagenase and activate latent enzyme in the stroma via plasminogen activator.大鼠乳腺癌细胞分泌活性胶原酶,并通过纤溶酶原激活剂激活基质中的潜伏酶。
Int J Cancer. 1981 Oct 15;28(4):509-15. doi: 10.1002/ijc.2910280418.
10
Characterization of plasminogen activators from normal human breast and colon and from breast and colon carcinomas.正常人乳腺和结肠以及乳腺癌和结肠癌中纤溶酶原激活剂的特性研究。
Int J Cancer. 1984 Sep 15;34(3):295-302. doi: 10.1002/ijc.2910340302.